|
| 37659962 | Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression. | Eur Urol | 2024 |
| 37659962 | Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression. | Eur Urol | 2024 |
| 36221864 | WHO 2022 classification of penile and scrotal cancers: updates and evolution. | Histopathology | 2023 |
| 36374194 | OncoLoop: A Network-Based Precision Cancer Medicine Framework. | Cancer Discov | 2023 |
| 36221864 | WHO 2022 classification of penile and scrotal cancers: updates and evolution. | Histopathology | 2023 |
| 36202687 | Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. | Eur Urol | 2023 |
| 36124685 | Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-β signaling in recurrent tumors. | Neuro Oncol | 2023 |
| 36779660 | Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma. | EMBO Mol Med | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 36749655 | DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations. | Cancer Res | 2023 |
| 36697832 | Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. | Nature | 2023 |
| 36796655 | PipeIT2: A tumor-only somatic variant calling workflow for molecular diagnostic Ion Torrent sequencing data. | Genomics | 2023 |
| 37295433 | Minor intron splicing is critical for survival of lethal prostate cancer. | Mol Cell | 2023 |
| 36724278 | PI5P4Kα supports prostate cancer metabolism and exposes a survival vulnerability during androgen receptor inhibition. | Sci Adv | 2023 |
| 37502956 | NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer. | bioRxiv | 2023 |
| 37546702 | The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer. | Cancer Res Commun | 2023 |
| 37546702 | The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer. | Cancer Res Commun | 2023 |
| 37502956 | NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer. | bioRxiv | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 37295433 | Minor intron splicing is critical for survival of lethal prostate cancer. | Mol Cell | 2023 |
| 36724278 | PI5P4Kα supports prostate cancer metabolism and exposes a survival vulnerability during androgen receptor inhibition. | Sci Adv | 2023 |
| 36697832 | Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. | Nature | 2023 |
| 36749655 | DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations. | Cancer Res | 2023 |
| 36779660 | Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma. | EMBO Mol Med | 2023 |
| 36796655 | PipeIT2: A tumor-only somatic variant calling workflow for molecular diagnostic Ion Torrent sequencing data. | Genomics | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 36374194 | OncoLoop: A Network-Based Precision Cancer Medicine Framework. | Cancer Discov | 2023 |
| 36202687 | Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. | Eur Urol | 2023 |
| 36124685 | Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-β signaling in recurrent tumors. | Neuro Oncol | 2023 |
| 33963663 | Histological and immunohistochemical investigation of canine prostate carcinoma with identification of common intraductal carcinoma component. | Vet Comp Oncol | 2022 |
| 35657155 | The evolving landscape of prostate cancer somatic mutations. | Prostate | 2022 |
| 35965208 | The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. | Eur Urol | 2022 |
| 35510953 | Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer. | J Exp Med | 2022 |
| 35758185 | WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. | Histopathology | 2022 |
| 35504881 | Alterations in homologous recombination repair genes in prostate cancer brain metastases. | Nat Commun | 2022 |
| 35502823 | An introduction to the WHO 5th edition 2022 classification of testicular tumours. | Histopathology | 2022 |
| 36344179 | Molecular Genetics of Prostate Cancer and Role of Genomic Testing. | Surg Pathol Clin | 2022 |
| 36075486 | Lineage plasticity in prostate cancer: Looking beyond intrinsic alterations. | Cancer Lett | 2022 |
| 35622144 | Towards a national strategy for digital pathology in Switzerland. | Virchows Arch | 2022 |
| 36055231 | Clinical application of advanced multi-omics tumor profiling: Shaping precision oncology of the future. | Cancer Cell | 2022 |
| 35853783 | The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. | Eur Urol | 2022 |
| 35596618 | WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. | Histopathology | 2022 |
| 36577525 | Whole-genome characterization of myoepithelial carcinomas of the soft tissue. | Cold Spring Harb Mol Case Stud | 2022 |
| 33963663 | Histological and immunohistochemical investigation of canine prostate carcinoma with identification of common intraductal carcinoma component. | Vet Comp Oncol | 2022 |
| 34628719 | Comparative pathology of dog and human prostate cancer. | Vet Med Sci | 2022 |
| 34676924 | Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors. | Adv Mater | 2022 |
| 34728552 | A Functional Precision Oncology Approach to Identify Treatment Strategies for Myxofibrosarcoma Patients. | Mol Cancer Res | 2022 |
| 35220606 | Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies. | J Pathol | 2022 |
| 35050902 | Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci. | JCI Insight | 2022 |